Comparative Pharmacology
Head-to-head clinical analysis: IMFINZI versus TECENTRIQ HYBREZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMFINZI versus TECENTRIQ HYBREZA.
IMFINZI vs TECENTRIQ HYBREZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Programmed cell death ligand 1 (PD-L1) inhibitor; binds to PD-L1 on tumor cells and immune cells, blocking interaction with PD-1 and B7.1 receptors on T cells, thereby restoring anti-tumor immune response.
Programmed death-ligand 1 (PD-L1) blocking antibody that binds to PD-L1, preventing interaction with PD-1 and B7.1, thereby reactivating antitumor immune responses.
10 mg/kg intravenously every 2 weeks for up to 12 months or until disease progression or unacceptable toxicity.
840 mg intravenously every 2 weeks, or 1200 mg intravenously every 3 weeks, or 1680 mg intravenously every 4 weeks.
None Documented
None Documented
The terminal elimination half-life (t1/2) is approximately 21 days (range: 14–27 days) in patients with advanced solid tumors. This long half-life supports a fixed dosing interval of every 2 or 4 weeks.
Terminal elimination half-life is approximately 6.5 days (range 4–9 days), supporting a subcutaneous dosing interval of every 3 weeks.
Durvalumab is eliminated primarily through catabolism into small peptides and amino acids. No significant renal or biliary excretion of intact drug occurs. Based on population pharmacokinetic analysis, the mean clearance (CL) is 0.235 L/day in patients with typical body weight (70 kg).
Almost entirely renal as unchanged drug (approximately 90% of a subcutaneously administered dose is eliminated via the kidneys within 96 hours). Biliary/fecal elimination accounts for less than 1%.
Category C
Category C
PD-L1 Inhibitor
Antineoplastic, PD-L1 Inhibitor